Duchenne Muscular Dystrophy News and Research

RSS
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Humans and mice have critical differences in gene responsible for DMD

Humans and mice have critical differences in gene responsible for DMD

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos third quarter 2009 financial results in line with management expectations

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

AMT's gene therapy successful in treating Duchenne muscular dystrophy

AMT's gene therapy successful in treating Duchenne muscular dystrophy

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Macrophages play a crucial role in muscle regeneration

Macrophages play a crucial role in muscle regeneration

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Safeway raises funds to support neuromuscular disease medical research and therapies

Safeway raises funds to support neuromuscular disease medical research and therapies

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics reports 2009 half year financials

New function for missing  protein in Duchenne muscular dystrophy found

New function for missing protein in Duchenne muscular dystrophy found

New therapy shows potential for treating Duchenne muscular dystrophy

New therapy shows potential for treating Duchenne muscular dystrophy

Inflammation clue to fragile bones in Duchenne's muscular dystrophy

Inflammation clue to fragile bones in Duchenne's muscular dystrophy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.